CTRI/2021/05/033568尚未招募4 期
An international Phase 4 field study to analyse the psychometric properties of the updated module on assessing quality of life of patients with breast cancer (EORTC QLQ-BR23 Update EORTC QLQ BR45). - EORTC BR45
Dr Vesna Bjelic Radisic0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1) Histologically confirmed diagnosis of breast cancer.
- •2) No previous primary or recurrent tumor.
- •3) Ability to understand the language of the questionnaire.
- •4) Mental fitness to complete a questionnaire.
- •5) Willing to provide written informed consent.
排除标准
- •Exclusion criteria are the negation of the inclusion criteria i.e., no histologically confirmed diagnosis of breast cancer, previous primary or recurrent tumor, not mentally fit to complete a questionnaire, not able to understand the language of the questionnaire, younger than 18, and refusal of informed consent.
研究者
相似试验
进行中（未招募）
不适用
An open, phase IV, multicentre, study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children aged 11-12 years, previously vaccinated with GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) or GSK Biologicals’ DTPa-IPV/Hib and HBV (Engerix™- B) vaccines at the ages of 3, 5 and 11 months in clinical trial DTPa-HBV-IPV-031 (217744/031). - DTPa-HBV-IPV-126 BST:031Antibody persistence and hepatitis B vaccine challenge at 11-12 years of age (excluding 13th birthday), after primary vaccination with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) or GSK Biologicals’ HBV vaccine (Engerix-B) given at the ages of 3, 5 and 11 months.EUCTR2009-016911-39-SKGlaxoSmithKline Biologicals
进行中（未招募）
1 期
A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different manufacturers in healthy and non-healthy adults aged > 41 years, approximately 48 months after primary vaccination in study 100382 (HAB-160). - HAB-168 BST:160EUCTR2008-000526-39-CZGlaxoSmithKline Biologicals333
进行中（未招募）
不适用
A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different manufacturers in healthy and non-healthy adults aged > 41 years, approximately 48 months after primary vaccination in study 100382 (HAB-160). - HAB-168 BST 160Healthy and non-healthy (including those taking medications) adults older than 41 years who participated in the primary vaccination study HAB-160 approximately 48 months ago.EUCTR2008-000526-39-BEGlaxoSmithKline Biologicals333
进行中（未招募）
不适用
Study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese infants who received hepatitis B immunoglobulin after birth.EUCTR2011-003731-63-Outside-EU/EEAGlaxoSmithKline Biologicals15
进行中（未招募）
1 期
A phase IV, open, multicenter, multicountry study to assess the long-term antibody persistence of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal serogroup C conjugate (Hib-MenC) vaccine given at 12-15 months of age to subjects who were primed in primary study 103974 (HIB-MENC-TT-012) and boosted in study 104056 (HIB-MENC-TT-013 BST:012). - Hib-MenC-TT-027, 028, 029EUCTR2006-006460-32-GBGlaxoSmithKline Biologicals478